title: Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies.
abstract: Few data are available regarding the 10-year survival among subjects with HIV and cancer. The aim of this study was to evaluate the 10-year survival of HIV-infected subjects with AIDS-defining malignancies (ADM) or non-AIDS-defining malignancies (NADM). This was a single center, retrospective, observational study of subjects with HIV infection and a subsequent cancer diagnosis; the data were collected from January 1991 to April 2010. Malignancies were divided into ADM or NADM on the basis of the Centre of Diseases Control-1993 classification. Survival curves were estimated using Kaplan-Meyer method and compared by the log-rank test. Six hundred and fifteen (9.5%) of the 6,495 subjects recorded in the San Raffaele Infectious Diseases Database developed a malignancy: 431 (70%) an ADM and 184 (30%) a NADM. In the case of ADM, survival was more favorable when cancer was diagnosed during post-highly active antiretroviral therapy (HAART) era (10-year survival: 43.2% ± 4.4%) than when diagnosed during the pre-HAART era (10-year survival: 16.4% ± 2.7%; log-rank test: p < 0.001). The same was true in the case of NADM (10-year survival: 44.7% ± 5.5% vs. 33.3 ± 9.6%; log-rank test: p = 0.03). An evaluation of survival probability by cancer type showed higher survival rates during the post-HAART era in the case of non-Hodgkin lymphoma (10-year survival: 42.1% ± 5.3% vs. 11.4% ± 3.3%; log-rank test: p = <0.001), Kaposi's sarcoma (10-year survival: 44.0% ± 8.4% vs. 23.5% ± 3.9%; log-rank test: p < 0.001) and Hodgkin's disease (10-year survival: 49.5% ± 14.5% vs. 40.0% ± 12.7%; log-rank test: p = 0.005). Despite the better cancer prognosis during the post-HAART era, the 10-year survival of HIV-infected subjects with an ADM or NADM is poor.
authors.affiliation: Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy. spagnuolo.vincenzo@hsr.it
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Spagnuolo
authors.forename: Laura
authors.initials: L
authors.lastname: Galli
authors.forename: Stefania
authors.initials: S
authors.lastname: Salpietro
authors.forename: Nicola
authors.initials: N
authors.lastname: Gianotti
authors.forename: Monica
authors.initials: M
authors.lastname: Guffanti
authors.forename: Francesca
authors.initials: F
authors.lastname: Cossarini
authors.forename: Alba
authors.initials: A
authors.lastname: Bigoloni
authors.forename: Paola
authors.initials: P
authors.lastname: Cinque
authors.forename: Simona
authors.initials: S
authors.lastname: Bossolasco
authors.forename: Giovanna
authors.initials: G
authors.lastname: Travi
authors.forename: Luca
authors.initials: L
authors.lastname: Fumagalli
authors.forename: Adriano
authors.initials: A
authors.lastname: Lazzarin
authors.forename: Antonella
authors.initials: A
authors.lastname: Castagna
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000453:epidemiology / Q000401:mortality*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000401:mortality*; D015497:HIV-1; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000453:epidemiology / Q000401:mortality*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate